Maximum Dose of Doxazosin for Hypertension
The maximum dose of doxazosin for hypertension is 16 mg once daily 1.
FDA-Approved Dosing
According to the FDA drug label, doxazosin dosing for hypertension follows this specific titration schedule 1:
- Initial dose: 1 mg once daily
- Titration: Daily dosage may be doubled up to 16 mg once daily, as needed, to achieve the desired reduction in blood pressure
- Maximum dose: 16 mg once daily
Critical Safety Considerations
Monitor blood pressure for at least 6 hours following the initial dose and with each dose increase 1. This is essential to detect first-dose hypotension and orthostatic effects.
If doxazosin is discontinued for several days, therapy must be restarted using the initial 1 mg dosing regimen—do not resume at the previous higher dose 1.
Clinical Context and Role in Hypertension Management
Position in Treatment Algorithm
Doxazosin is not a first-line agent for hypertension. Current guidelines position it as a fourth- or fifth-line option for resistant hypertension 2, 3, 4:
- First-line: ACE inhibitors/ARBs, dihydropyridine CCBs, thiazide/thiazide-like diuretics
- Second-line: Combination of the above
- Third-line: Triple combination (RAS blocker + CCB + diuretic)
- Fourth-line: Add spironolactone (preferred), or if not tolerated/contraindicated, consider doxazosin, amiloride, eplerenone, clonidine, or beta-blocker
Evidence for Efficacy at Maximum Doses
Clinical trial data demonstrates that doxazosin at doses ranging from 1-16 mg once daily effectively lowers blood pressure by approximately 10/8 mmHg compared to placebo in standing position and 9/5 mmHg in supine position 1. The mean effective dose in clinical practice studies was approximately 4-7 mg daily 5, 6, 7.
In resistant hypertension specifically, doxazosin added as a fifth-line agent (mean dose 6.9 mg, range 2-16 mg) reduced blood pressure from 159/92 mmHg to 126/73 mmHg over 21 months of follow-up 5. When added as third-line therapy in the ASCOT-BPLA trial, doxazosin (mean final dose 7.0 mg) reduced blood pressure by 11.7/6.9 mmHg 7.
Practical Dosing in Clinical Practice
While 16 mg is the FDA-approved maximum, most patients achieve blood pressure control at lower doses:
- 76% of responders achieved control at a mean dose of 3.3 mg daily 8
- Mean effective doses in studies ranged from 4.1-7.0 mg daily 6, 7
- Doses above 8 mg are rarely needed but can be used if lower doses are insufficient and the medication is well-tolerated
Common Pitfalls
Orthostatic hypotension and first-dose syncope are the primary concerns, particularly in elderly patients, those on multiple antihypertensives, or volume-depleted patients 9, 1. The extended-release GITS formulation may reduce these effects compared to immediate-release 7, 10.
Discontinuation rates due to adverse events (dizziness, fatigue, headache, edema) are approximately 7.5% 7, though tolerability is generally good with only 5.2% discontinuation in resistant hypertension cohorts 5.